Trends in statin use in seniors 1999 to 2013: Time series analysis

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Minard, Laura V ^a   Corkum, Amber ^b   Sketris, Ingrid ^a   Fisher, Judith ^c   Zhang, Ying ^b   Saleh, Ahmed ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b ACADIA UNIVERSITY   (Canada)

^c Nova Scotia Department of Health Promotion and Protection   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; PRESCRIPTION DRUG;

AGED; ARTICLE; DRUG MARKETING; DRUG PROGRAM; DRUG USE; DRUG UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; TREND STUDY; ATTITUDE TO HEALTH; CLINICAL TRIAL (TOPIC); EPIDEMIOLOGY; FEMALE; MALE; NOVA SCOTIA; RETROSPECTIVE STUDY; SUPPLY AND DISTRIBUTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATORVASTATIN CALCIUM; CLINICAL TRIALS AS TOPIC; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INDOLES; INTERRUPTED TIME SERIES ANALYSIS; LOVASTATIN; MALE; NOVA SCOTIA; PRAVASTATIN; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; ROSUVASTATIN CALCIUM; SIMVASTATIN;

EID: 84979561956     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158608     Document Type: Article

References (59)

1. Ioannidis JP. More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. JAMA 2014; 311(5): 463-464. doi: 10.1001/jama.2013.284657 PMID: 24296612
2. Canadian Institute of Health Information. Drivers of prescription drug spending in Canada. http://www.cihi.ca/cihi-ext-portal/pdf/internet/drug-spend-drivers-en (accessed 15 June 2014).
3. Sketris IS, Langille Ingram EM, Lummis HL. Strategic opportunities for effective optimal prescribing and medication management. Can J Clin Pharmacol 2009; 16(1):e103-25. PMID: 19182305
4. Niederdeppe J, Byrne S, Avery RJ, Cantor J. Direct-to-consumer television advertising exposure, diagnosis with high cholesterol, and statin use. J Gen Intern Med 2013; 28(7):886-93. doi: 10.1007/s11606-013-2379-3 PMID: 23463454
5. Pichetti S, Sermet C, Godman B, Campbell SM, Gustafsson LL. Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France. Appl Health Econ Health Policy 2013; 11:205-18. doi: 10.1007/s40258-013-0014-4 PMID: 23609765
6. Mamdani MM, Tu JV. Did the major clinical trials of statins affect prescribing behaviour? CMAJ 2001; 164(12):1695-6. PMID: 11450211
7. Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of the statins in patients after acute myocardial infarction: does evidence change practice? Arch Intern Med 2001; 161(2):183-8. PMID: 11176731
8. Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007; 100(11): 1659-64. PMID: 18036365
9. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21):2195-207. doi: 10.1056/NEJMoa0807646 PMID: 18997196
10. Statistics Canada. Focus on geography series, 2011 Census. https://www12.statcan.gc.ca/census-recensement/2011/as-sa/fogs-spg/Facts-pr-eng.cfm?LANG=Eng&GK=PR&GC=12 (accessed 11 August 2014).
11. Canadian Institute of Health Information. Drug use in seniors on public drug programs, 2012. https://secure.cihi.ca/free-products/Drug-Use-in-Seniors-on-Public-Drug-Programs-2012-EN-web.pdf, May 2014 (accessed 26 August 2014).
12. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27(4):299-309. PMID: 12174032
13. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005; 60(5):543-51. PMID: 16236045
14. Wallach Kildemoes H, Vass M, Hendriksen C, Andersen M. Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. Health Policy 2012; 108(2-3):216-27. doi: 10.1016/j.healthpol.2012.08.008 PMID: 22975117
15. Fraeyman J, Van Hal G, Godman B, Beutels P. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. Expert Rev Pharmacoecon Outcomes Res 2013; 13(1):141-51. doi: 10.1586/erp.12.88 PMID: 23402454
16. Rikala M, Huupponen R, Helin-Salmivaara A, Korhonen MJ. Channelling of statin use towards low-risk population and patients with diabetes. Basic Clin Pharmacol Toxicol 2013; 113(3):173-8. doi: 10.1111/bcpt.12075 PMID: 23574641
17. Charlesworth CJ, Smit E, Lee DS, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci 2015; 70(8):989-95. doi: 10.1093/gerona/glv013 PMID: 25733718
18. Mintzes B, Morgan S, Wright JM. Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale. PLoS One 2009; 4(5):e5699. doi: 10.1371/journal.pone.0005699 PMID: 19479084
19. Teng JF, Gomes T, Camacho X, Grundy S, Juurlink DN, Mamdani MM. Impact of the JUPITER trial on statin prescribing for primary prevention. Pharmacotherapy 2014; 34(1):9-18. doi: 10.1002/phar.1340 PMID: 23940007
20. Spatz ES, Canavan ME, Desai MM. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes 2009; 2(1):41-8. doi: 10.1161/CIRCOUTCOMES.108.832592 PMID: 20031811
21. Nanchen D, Pletcher MJ, Cornuz J, Marques-Vidal PM, Paccaud F, Waeber G, et al. Public health impact of statin prescribing strategies based on JUPITER. Prev Med 2011; 52(2):159-63. doi: 10.1016/j.ypmed.2010.11.018 PMID: 21130802
22. National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report (2002). NIH Publication No. 02-5215. Bethesda, MD: National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health.
23. Galper BZ, Wang YC, Einstein AJ. Strategies for primary prevention of coronary heart disease based on risk stratification by the ACC/AHA lipid guidelines, ATP III guidelines, coronary calcium scoring, and C-reactive protein, and a global treat-all strategy: a comparative-effectiveness modeling study. PLoS One 2015; 10(9);e0138092. doi: 10.1371/journal.pone.0138092 PMID: 26422204
24. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359(18):1897-908. doi: 10.1056/NEJMoa0707402 PMID: 18971492
25. Jackson G, Citrome L. JUPITER: Wake up and smell the coffee-the absolute and relative merits of statin use. Int J Clin Pract 2009; 63(3):347-8. doi: 10.1111/j.1742-1241.2009.02013.x PMID: 19222618
26. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5 PMID: 19329177
27. Shishehbor MH, Hazen SL. Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean? Cleve Clin J Med 2009; 76(1):37-44. doi: 10.3949/ccjm.75a.08105 PMID: 19122109
28. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. JUPITER: major implications for vascular risk assessment. Curr Med Res Opin 2009; 25(1):133-7. doi: 10.1185/03007990802643557 PMID: 19210146
29. Nissen SE. The JUPITER trial: key findings, controversies, and implications. Curr Cardiol Rep 2009; 11(2):81-2. PMID: 19236822
30. Yusuf S, Lonn E, Bosch J. Lipid lowering for primary prevention. Lancet 2009; 373(9670): 1152-5. doi: 10.1016/S0140-6736(09)60357-3 PMID: 19345816
31. de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med 2010; 170(12):1032-6. doi: 10.1001/archinternmed.2010.184 PMID: 20585068
32. Schneemann M, Baechli E, Perumpanani A. Who brewed the coffee on JUPITER: it was Dr Knock! Int J Clin Pract 2009; 63(7):1118.
33. Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol 2009; 104(11):1603-5. doi: 10.1016/j.amjcard.2009.07.033 PMID: 19932800
34. Yang EY, Nambi V, Tang Z, Virani SS, Boerwinkle E, Hoogeveen RC, et al. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2009; 54(25):2388-95. doi: 10.1016/j.jacc.2009.10.006 PMID: 20082929
35. Slejko JF, Page RL 2nd, Sullivan PW. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Curr Med Res Opin 2010; 26(10):2485-97. doi: 10.1185/03007995.2010.516994 PMID: 20828360
36. Ridker PM, Glynn RJ. The JUPITER trial: responding to the critics. Am J Cardiol 2010; 106(9):1351-6. doi: 10.1016/j.amjcard.2010.08.025 PMID: 21029837
37. Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease - a perspective. Drug Des Devel Ther 2010; 4:383-413. doi: 10.2147/DDDT.S10812 PMID: 21267417
38. Gupta M, Singh N, Tsigoulis M, Kajil M, Hirjikaka S, Quan A, et al. Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management. Can J Cardiol 2012; 28(1):14-9. doi: 10.1016/j.cjca.2011.09.014 PMID: 22264843
39. Kwon HY, Godman B. Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications. BMC Health Serv Res 2016; 16(1):130. doi: 10.1186/s12913-016-1356-z PMID: 27080530
40. Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med 2015; 13:173. doi: 10.1186/s12916-015-0415-3 PMID: 26224091
41. Manzoli L, Flacco ME, Boccia S, D'Andrea E, Panic N, Marzuillo C, et al. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol 2015 Nov 30 [epub ahead of print].
42. Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Liu J, et al. State generic substitution laws can lower drug outlays under Medicaid. Health Aff (Millwood) 2010; 29(7);1383-90.
43. Patel MS, Day S, Small DS, Howell JT 3rd, Lautenbach GL, Nierman EH, et al. Using default options within the electronic health record to increase the prescribing of generic-equivalent medications: a quasi-experimental study. Ann Intern Med 2014; 161(10 Suppl):S44-52. doi: 10.7326/M13-3001 PMID: 25402402
44. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15):1495-504. PMID: 15007110
45. Statins and cardiovascular disease. Dalhousie CME Academic Detailing Service, April 2005.
46. Polinksi JM, Maclure M, Marshall B, Cassels A, Agnew-Blais J, Patrick AR, et al. Does knowledge of medication prices predict physicians' support for cost effective prescribing policies. Can J Clin Pharmacol 2008; 15(2):e286-94. PMID: 18641423
47. Meissner B, Dickson M, Shinogle J, Reeder CE, Belazi D, Senevirante V. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. J Manag Care Pharm 2006; 12(4):331-40. PMID: 16792439
48. Winkelmayer WC, Asslaber M, Bucsics A, Burkhardt T, Schautzer A, Wieninger P, et al. Impact of reimbursement changes on statin use among patients with diabetes in Austria. Wien Klin Wochenschr 2010; 122(3-4):89-94. doi: 10.1007/s00508-009-1292-6 PMID: 20213375
49. Carrera M, Goldman D, Joyce G, Sood N. Do physicians respond to the costs and cost-sensitivity of their patients? Am Econ J. Forthcoming 2016.
50. Lindgren P and Jönsson B. Cost-effectiveness of statins revisited: lessons learned about the value of innovation. Eur J Health Econ 2012; 13(4):445-50. doi: 10.1007/s10198-011-0315-1 PMID: 21528389
51. Brown JD, Doshi PA, Talbert JC. Utilization of free medication samples in the United States in a nationally representative sample: 2009-2013. Res Social Adm Pharm 2016 Jan 30 [epub ahead of print].
52. Wieringa S, Greenhalgh T. 10 years of mindlines: a sytematic review and commentary. Implement Sci 2015; 10:45. doi: 10.1186/s13012-015-0229-x PMID: 25890280
53. Launer J. Guidelines and Mindlines. Postgrad Med J 2015; 91(1081):663-4. doi: 10.1136/postgradmedj-2015-133766 PMID: 26500012
54. Sullivan HW, Campbell M. Do prescription drug ads tell consumers enough about benefits and side effects? Results from the health information national trends survey, fourth administration. J Health Commun 2015; 20(12):1391-6. doi: 10.1080/10810730.2015.1018635 PMID: 26120940
55. Murphy AL, Fleming M, Martin-Misener R, Sketris IS, MacCara M, Gass D. Drug information resources used by nurse practitioners and collaborating physicians at the point of care in Nova Scotia, Canada: a survey and review of the literature. BMC Nurs 2006; 5:5. PMID: 16822323
56. Lipid lowering in primary prevention: a calculated risk. Dalhousie CME Academic Detailing Service, February 2013. http://cme.medicine.dal.ca/ad-resources.htm (accessed August 30, 2014).
57. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63(25 Pt B):2889-934. doi: 10.1016/j.jacc.2013.11.002 PMID: 24239923
58. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ 2013; 347:f6123. doi: 10.1136/bmj.f6123 PMID: 24149819
59. Barrett B, Ricco J, Wallace M, Kiefer D, Rakel D. Communicating statin evidence to support shared decision-making. BMC Fam Pract 2016; 17:41. doi: 10.1186/s12875-016-0436-9 PMID: 27048421